Why this seasoned money manager sees real upside for this innovative B2B tech startup. on 10/26/2021. Learn More

Sector Expert: Domenic Della Penna

Intellipharmaceutics International Inc.

Image: Domenic Della Penna

Domenic Della Penna, CFO, joined Intellipharmaceutics International in November 2014. Mr. Della Penna brings considerable expertise and industry experience to the company, having held senior posts at several industry leading multinationals. He previously served as CFO of Teva Canada Ltd. since December 2010, and he simultaneously served as interim CFO of Teva North America Generics in the United States since December 2013. His responsibilities and accomplishments in those roles included enhancements to strategic planning processes and financial systems, integration of assets acquired in the purchase of ratiopharm Canada by Teva, business development and the negotiation of in-licensing opportunities, mergers and acquisitions. Prior to his time at Teva, Mr. Della Penna was the CFO of Timothy's Coffees of the World, vice president of finance of Diageo Canada Inc., and vice president of finance Nestle Canada Inc. (Ice Cream division). In all these roles, Mr. Della Penna made significant contributions to various mergers, acquisitions, divestitures and organizational change mandates. Mr. Della Penna is a Chartered Accountant (CA), a Chartered Professional Accountant (CPA), and holds a master's degree in business administration from the Schulich School of Business at York University (Toronto).

Recent Interviews

Dialing Back Euphoria: The Intellipharmaceutics Prescription for Opioid Abuse (5/11/16)

Opioid abuse has moved front and center in the political and social arena, sparked in recent weeks by the still-unexplained death of music legend Prince. Heroin is the headline, but addiction to prescription painkillers, like those reportedly used by the pop icon to control chronic pain, runs a close second. How can the biotech industry deter abuse of drugs like oxycodone? Intellipharmaceutics International has a potential solution, Chief Financial Officer Domenic Della Penna tells The Life Sciences Report, as well as a robust pipeline of generic options for a variety of indications.

Due to permission requirements, not all quotes are shown.